Evommune has secured exclusive rights outside Greater China to develop EVO570 from Hinova Pharmaceuticals in a deal worth up to $1.1 billion. This agreement highlights the growing interest in innovative therapies and the potential for significant financial investment in drug development. Such licensing deals may indicate a trend towards collaboration in the biopharma industry, allowing companies to leverage each other’s strengths and expand their product portfolios.
Source: pharmaceutical-technology.com · Image: Utah Airman supports pharmaceutical operations during African Lion 2025 (9057969) by U.S. Army SETAF-AF by Master Sgt. Nicholas Perez, Public domain, via Wikimedia Commons
Affordable access, full power:
For just $42 per month, the “Solo” plan unlocks the same API & FDF Intelligence data used by global companies.
You instantly see price ranges, dossiers, and certificates — and, most importantly, gain direct contacts to every manufacturer and FDF holder.
It’s a practical way to work with reliable data without heavy budgets.
Get started today with Solo access →
Get started today with Solo access →
